Annual SG&A
$2.88 M
-$2.97 M-50.75%
31 December 2022
Summary:
Nymox Pharmaceutical annual selling, general & administrative expenses is currently $2.88 million, with the most recent change of -$2.97 million (-50.75%) on 31 December 2022. During the last 3 years, it has fallen by -$722.00 thousand (-20.05%).NYMX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$665.00 K
+$88.00 K+15.25%
31 March 2023
Summary:
Nymox Pharmaceutical quarterly selling, general & administrative expenses is currently $665.00 thousand, with the most recent change of +$88.00 thousand (+15.25%) on 31 March 2023.NYMX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$793.77 M
-$2.88 M-0.36%
31 March 2023
Summary:
Nymox Pharmaceutical TTM selling, general & administrative expenses is currently -$793.77 million, with the most recent change of -$2.88 million (-0.36%) on 31 March 2023.NYMX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NYMX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -20.1% | -54.4% | -10000.0% |
| 5 y5 years | -30.2% | -34.9% | -10000.0% |
NYMX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -75.2% | -86.2% | -6293.3% |
Nymox Pharmaceutical Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | $665.00 K(+15.3%) | $2.80 M(-2.6%) |
| Dec 2022 | $2.88 M(-50.8%) | $577.00 K(-2.0%) | $2.87 M(-23.5%) |
| Sept 2022 | - | $589.00 K(-39.0%) | $3.76 M(-18.8%) |
| June 2022 | - | $966.00 K(+30.5%) | $4.63 M(-17.0%) |
| Mar 2022 | - | $740.00 K(-49.3%) | $5.58 M(-4.5%) |
| Dec 2021 | $5.85 M(+62.3%) | $1.46 M(+0.1%) | $5.84 M(+12.5%) |
| Sept 2021 | - | $1.46 M(-23.9%) | $5.19 M(+11.6%) |
| June 2021 | - | $1.92 M(+90.8%) | $4.65 M(+32.5%) |
| Mar 2021 | - | $1.00 M(+24.0%) | $3.51 M(-2.0%) |
| Dec 2020 | $3.60 M(-40.0%) | $810.00 K(-12.0%) | $3.58 M(-3.1%) |
| Sept 2020 | - | $920.00 K(+18.6%) | $3.70 M(-2.7%) |
| June 2020 | - | $776.00 K(-27.9%) | $3.80 M(-35.7%) |
| Mar 2020 | - | $1.08 M(+16.7%) | $5.90 M(-2.0%) |
| Dec 2019 | $6.01 M(+45.6%) | $923.00 K(-9.6%) | $6.02 M(-1.6%) |
| Sept 2019 | - | $1.02 M(-64.6%) | $6.12 M(-2.4%) |
| June 2019 | - | $2.88 M(+141.2%) | $6.27 M(+45.0%) |
| Mar 2019 | - | $1.20 M(+16.8%) | $4.32 M(+10.2%) |
| Dec 2018 | $4.13 M(-24.1%) | $1.02 M(-12.6%) | $3.92 M(+3.0%) |
| Sept 2018 | - | $1.17 M(+25.2%) | $3.81 M(-24.6%) |
| June 2018 | - | $935.00 K(+17.8%) | $5.05 M(-1.2%) |
| Mar 2018 | - | $794.00 K(-12.7%) | $5.11 M(-6.0%) |
| Dec 2017 | $5.44 M(-12.1%) | $909.00 K(-62.3%) | $5.43 M(-4.4%) |
| Sept 2017 | - | $2.41 M(+142.7%) | $5.68 M(+30.1%) |
| June 2017 | - | $994.00 K(-11.2%) | $4.37 M(-23.9%) |
| Mar 2017 | - | $1.12 M(-3.2%) | $5.74 M(-7.2%) |
| Dec 2016 | $6.18 M(-46.8%) | $1.16 M(+5.4%) | $6.18 M(-7.4%) |
| Sept 2016 | - | $1.10 M(-53.6%) | $6.68 M(-35.5%) |
| June 2016 | - | $2.37 M(+51.4%) | $10.35 M(-19.2%) |
| Mar 2016 | - | $1.56 M(-5.5%) | $12.82 M(+10.4%) |
| Dec 2015 | $11.61 M(+286.6%) | $1.65 M(-65.3%) | $11.61 M(+9.2%) |
| Sept 2015 | - | $4.77 M(-1.2%) | $10.64 M(+66.4%) |
| June 2015 | - | $4.83 M(+1248.8%) | $6.39 M(+209.7%) |
| Mar 2015 | - | $358.10 K(-47.2%) | $2.06 M(-31.3%) |
| Dec 2014 | $3.00 M(+47.4%) | $678.00 K(+29.1%) | $3.00 M(+8.4%) |
| Sept 2014 | - | $525.00 K(+4.4%) | $2.77 M(-2.6%) |
| June 2014 | - | $502.70 K(-61.3%) | $2.84 M(-1.1%) |
| Mar 2014 | - | $1.30 M(+191.4%) | $2.88 M(+41.2%) |
| Dec 2013 | $2.04 M(-4.4%) | $445.40 K(-25.6%) | $2.04 M(+2.6%) |
| Sept 2013 | - | $598.60 K(+12.0%) | $1.99 M(+4.7%) |
| June 2013 | - | $534.50 K(+16.3%) | $1.90 M(-6.7%) |
| Mar 2013 | - | $459.40 K(+16.9%) | $2.03 M(-4.6%) |
| Dec 2012 | $2.13 M(-38.7%) | $393.10 K(-22.9%) | $2.13 M(-3.4%) |
| Sept 2012 | - | $509.60 K(-24.1%) | $2.21 M(-9.2%) |
| June 2012 | - | $671.40 K(+20.6%) | $2.43 M(+5.6%) |
| Mar 2012 | - | $556.50 K(+19.0%) | $2.30 M(-33.2%) |
| Dec 2011 | $3.48 M(+73.8%) | $467.70 K(-36.3%) | $3.44 M(-12.1%) |
| Sept 2011 | - | $733.80 K(+35.4%) | $3.92 M(+11.0%) |
| June 2011 | - | $541.80 K(-68.1%) | $3.53 M(+3.3%) |
| Mar 2011 | - | $1.70 M(+80.7%) | $3.41 M(+70.7%) |
| Dec 2010 | $2.00 M | $940.80 K(+172.8%) | $2.00 M(+34.9%) |
| Sept 2010 | - | $344.90 K(-19.5%) | $1.48 M(-11.9%) |
| June 2010 | - | $428.20 K(+49.9%) | $1.68 M(-3.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2010 | - | $285.70 K(-32.5%) | $1.75 M(-13.5%) |
| Dec 2009 | $2.02 M(-7.1%) | $423.20 K(-22.4%) | $2.02 M(-5.2%) |
| Sept 2009 | - | $545.30 K(+9.9%) | $2.13 M(+1.0%) |
| June 2009 | - | $496.20 K(-11.2%) | $2.11 M(-2.6%) |
| Mar 2009 | - | $558.70 K(+4.5%) | $2.17 M(-0.3%) |
| Dec 2008 | $2.18 M(-2.0%) | $534.50 K(+1.8%) | $2.18 M(+0.6%) |
| Sept 2008 | - | $524.90 K(-4.9%) | $2.16 M(-6.9%) |
| June 2008 | - | $552.20 K(-2.4%) | $2.33 M(+3.0%) |
| Mar 2008 | - | $566.00 K(+8.5%) | $2.26 M(+1.7%) |
| Dec 2007 | $2.22 M(+9.6%) | $521.50 K(-24.0%) | $2.22 M(+2.5%) |
| Sept 2007 | - | $686.10 K(+41.4%) | $2.17 M(+5.0%) |
| June 2007 | - | $485.10 K(-8.1%) | $2.06 M(-10.3%) |
| Mar 2007 | - | $527.90 K(+13.2%) | $2.30 M(+13.3%) |
| Dec 2006 | $2.03 M(+35.9%) | $466.40 K(-20.0%) | $2.03 M(+4.5%) |
| Sept 2006 | - | $582.90 K(-19.1%) | $1.94 M(+11.8%) |
| June 2006 | - | $720.90 K(+179.6%) | $1.74 M(+28.6%) |
| Mar 2006 | - | $257.80 K(-32.0%) | $1.35 M(-9.6%) |
| Dec 2005 | $1.49 M(+1.7%) | $379.10 K(+0.5%) | $1.49 M(-0.4%) |
| Sept 2005 | - | $377.40 K(+12.5%) | $1.50 M(+5.8%) |
| June 2005 | - | $335.40 K(-16.4%) | $1.42 M(-6.8%) |
| Mar 2005 | - | $401.10 K(+4.3%) | $1.52 M(+3.5%) |
| Dec 2004 | $1.47 M(-2.8%) | $384.70 K(+30.2%) | $1.47 M(-3.8%) |
| Sept 2004 | - | $295.40 K(-32.6%) | $1.52 M(-1.1%) |
| June 2004 | - | $438.10 K(+25.4%) | $1.54 M(-0.5%) |
| Mar 2004 | - | $349.50 K(-20.9%) | $1.55 M(+2.5%) |
| Dec 2003 | $1.51 M(+2.9%) | $442.00 K(+41.7%) | $1.51 M(+9.7%) |
| Sept 2003 | - | $312.00 K(-30.0%) | $1.38 M(-6.4%) |
| June 2003 | - | $445.80 K(+43.2%) | $1.47 M(-1.6%) |
| Mar 2003 | - | $311.30 K(+1.0%) | $1.50 M(+2.1%) |
| Dec 2002 | $1.47 M(+2.5%) | $308.10 K(-24.3%) | $1.47 M(-11.3%) |
| Sept 2002 | - | $406.90 K(-13.5%) | $1.65 M(+8.0%) |
| June 2002 | - | $470.20 K(+67.6%) | $1.53 M(+3.3%) |
| Mar 2002 | - | $280.50 K(-43.3%) | $1.48 M(+3.5%) |
| Dec 2001 | $1.43 M(-15.8%) | $494.70 K(+74.3%) | $1.43 M(+85.8%) |
| Sept 2001 | - | $283.90 K(-32.6%) | $769.60 K(-26.3%) |
| June 2001 | - | $421.30 K(+83.0%) | $1.04 M(-24.4%) |
| Mar 2001 | - | $230.20 K(-238.8%) | $1.38 M(-9.3%) |
| Dec 2000 | $1.70 M(-21.8%) | -$165.80 K(-129.7%) | $1.52 M(-32.7%) |
| Sept 2000 | - | $559.10 K(-26.2%) | $2.26 M(-5.8%) |
| June 2000 | - | $757.90 K(+103.7%) | $2.40 M(+23.6%) |
| Mar 2000 | - | $372.00 K(-35.1%) | $1.94 M(-14.4%) |
| Dec 1999 | $2.17 M(-22.3%) | $573.40 K(-18.0%) | $2.27 M(-4.9%) |
| Sept 1999 | - | $699.40 K(+134.3%) | $2.39 M(-0.1%) |
| June 1999 | - | $298.50 K(-57.4%) | $2.39 M(-14.4%) |
| Mar 1999 | - | $700.20 K(+1.4%) | $2.79 M(-3.4%) |
| Dec 1998 | $2.80 M(+64.6%) | $690.20 K(-1.6%) | $2.89 M(+15.7%) |
| Sept 1998 | - | $701.70 K(+0.2%) | $2.50 M(+19.1%) |
| June 1998 | - | $700.40 K(-12.4%) | $2.10 M(+5.0%) |
| Mar 1998 | - | $799.40 K(+167.6%) | $2.00 M(+66.7%) |
| Dec 1997 | $1.70 M | $298.70 K(-0.4%) | $1.20 M(+33.2%) |
| Sept 1997 | - | $299.90 K(-50.0%) | $899.80 K(+50.0%) |
| June 1997 | - | $599.90 K | $599.90 K |
FAQ
- What is Nymox Pharmaceutical annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Nymox Pharmaceutical?
What is Nymox Pharmaceutical annual selling, general & administrative expenses?
The current annual SG&A of NYMX is $2.88 M
What is the all time high annual SG&A for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high annual selling, general & administrative expenses is $11.61 M
What is Nymox Pharmaceutical quarterly selling, general & administrative expenses?
The current quarterly SG&A of NYMX is $665.00 K
What is the all time high quarterly SG&A for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high quarterly selling, general & administrative expenses is $4.83 M
What is Nymox Pharmaceutical TTM selling, general & administrative expenses?
The current TTM SG&A of NYMX is -$793.77 M
What is the all time high TTM SG&A for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high TTM selling, general & administrative expenses is $12.82 M